 | Up a level |
Ossenkoppele, G J; Breems, D A; Stuessi, G; van Norden, Y; Bargetzi, M; Biemond, B J; A von dem Borne, P; Chalandon, Y; Cloos, J; Deeren, D; Fehr, M; Gjertsen, B; Graux, C; Huls, G; Janssen, J J J W; Jaspers, A; Jongen-Lavrencic, M; de Jongh, E; Klein, S K; van der Klift, M; ... (2020). Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS. Leukemia, 34(7), pp. 1751-1759. Nature Publishing Group 10.1038/s41375-020-0725-0
Terwijn, M.; van Putten, W. L. J.; Kelder, A.; van der Velden, V. H. J.; Brooimans, R. A.; Pabst, T.; Maertens, J.; Boeckx, N.; de Greef, G. E.; Valk, P. J. M.; Preijers, F. W. M. B.; Huijgens, P. C.; Drager, A. M.; Schanz, U.; Jongen-Lavrecic, M.; Biemond, B. J.; Passweg, J. R.; van Gelder, M.; Wijermans, P.; Graux, C.; ... (2013). High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study. Journal of clinical oncology, 31(31), pp. 3889-3897. American Society of Clinical Oncology 10.1200/JCO.2012.45.9628
